Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio ...

With decades of hands-on experience, Sharp’s industry experts reveal their top five recommendations for a timely and ...

The clinical success of CRISPR-based treatments is fundamentally dependent on sophisticated gRNA targeting systems that ...

Though the FDA will continue its core activities, the agency will no longer be accepting NDAs and BLAs until the ...

Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, adding microparticle capabilities ...

During HUAWEI CONNECT 2025, Leo Chen, Senior Vice President, President of Enterprise Sales, Huawei, emphasised the focus is ...

Though unexpected CRLs issued by the FDA have caused ripples in the industry, Becky Wood believes that these cases are the ...

Biopharmaceutical innovation can cost billions and take over a decade to bear fruit. Salvation lies in swapping paper trails ...

The Massachusetts bioresearch centre expansion is part of AbbVie’s wider ploy to bolster its US operations amid Trump tariff ...

Orphan drugs are therapeutics developed to address rare diseases typically defined by patient population thresholds that vary ...

We caught up with the team behind the first ever mobile leukapheresis center to see what community-based care could look like ...